Ulf Jungnelius MD, CEO, Isofol Medical discusses the increasing incidence of colorectal cancer as a global issue and the current challenges in treating this devastating disease.  Dr. Jungnelius also talks about the company’s drug candidate, arfolitixorin, currently being studied in a global Phase 3 clinical trial with the aim to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer.